STOCKHOLM--(BUSINESS WIRE)--Regulatory News: In connection with the acquisition of Corvette Pharmaceutical Services Group completed on October 1, 2014, Recipharm AB (STO: RECI)(“Recipharm”) issued convertible bonds with a nominal value of EUR 50 million as part of the financing of the acquisition. The convertible bonds can be converted into up to 5,030,549 class B-shares. The holders of the convertible bonds have agreed to a lock-up in respect of the new shares issued upon conversion until 14 February, 2015.
Help employers find you! Check out all the jobs and post your resume.
